Liang Ding

Director CMC Analytical

Liang joins Aceragen with CMC analytical and bioanalytical experiences in drug development for rare diseases. Before joining Aceragen, Liang worked at CRISPR Therapeutics, Homology Medicines, and Tessera Therapeutics, where he and his team developed analytical methods to characterize and quality control a range of modalities, Cas9/gRNA, mRNA, lipid nanoparticles, virus, and proteins. Liang is also passionate and insightful about the scientific and technological aspects of process development.